The purpose of this study is to evaluate the efficacy and safety of tri-weekly ABI-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease progression or recurrence.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
56
ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
Shikoku Cancer Center
Matsuyama, Ehime, Japan
National Kyusyu Cancer Center
Fukuoka, Fukuoka, Japan
Overall response rate
Time frame: During chemotherapy
Safety
Time frame: During chemotherapy
Progression-free survival
Time frame: Until progression
Overall survival
Time frame: Over a year form randomaization
Disease control rate
Time frame: Duration chemoterapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Kitasato University East Hospital
Sagamihara, Kanagawa, Japan
Kochi Health Sciences Center
Kochi, Kochi, Japan
Saku Central Hospital Nagano Prefectural Federation of Agricultural Cooperatives for Health and Welfare
Saku, Nagano, Japan
Osaka Medical College Hospital
Takatsuki, Osaka, Japan
Saitama International medical center-comprehensive cancer center, Saitama Medical University
Hidaka, Saitama, Japan
Shizuoka Cancer Center
Sunto, Shizuoka, Japan
Kouseiren Takaoka Hospital
Takaoka, Toyama, Japan